Form D · Biotechnology
Discgenics, Inc.
Salt Lake City, UT · CIK 0001503545
Offering snapshot reported May 16, 2013 · SEC filing
- Reported sold
- Yet to sell Offering amount: $3M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 16, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Oct 21, 2011 | Amendment | $1,839,000 | $969,000vs Oct 21, 2010 | 17 | SEC filing |
| Oct 21, 2010 | Initial | $870,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-196613
Source: Form D, filed May 16, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark S. Cohen | Director |
| Christopher D. Duntsch, M.D., Ph.D. | Director, Executive |
| J. Flagg Flanagan | Director, Executive |
| Kevin T. Foley | Director |
| Kevin T. Foley, M.D. | Director, Executive |
| Mike Moffat | Executive |
| Robert M. Wynalek | Director, Executive |
| Greg A. Ziskind | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
675 Arapeen Dr. Suite 304
Salt Lake City, UT, 84108
Salt Lake City, UT, 84108